Status: Not yet recruiting
DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric Cancer
To address regional disparity, the investigators propose a tailored perioperative strategy for East Asian patients, combining neoadjuvant FLOT plus durvalumab, followed by adjuvant TS-1 plus durvalumab. This approach seeks to balance efficacy, immunologic synergy, and treatment tolerability, offering a more practical regimen for Eastern populations.
Participants needed: 35
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Taipei Veterans General Hospital, TaiwanUpdated: Aug 11, 2026Locations: 1
Eligibility criteria
Capable of giving signed informed consent which includes compliance with the req... [+14]
Patients with peritoneal dissemination (including tumor cells in peritoneal flui... [+26]